ALG13 X‐linked intellectual disability: New variants, glycosylation analysis, and expanded phenotypes
暂无分享,去创建一个
H. Freeze | K. Bilguvar | J. Christodoulou | B. Cogné | Sheng-Chih Jin | M. He | W. Deb | Jie Chen | D. Amor | K. Raymond | E. Jones | Dong Li | E. Bhoj | M. Kruer | M. Vincent | A. Edmondson | S. Bakhtiari | R. Webster | Andrew C. Edmondson | G. Vassallo | Andrew K. Sobering | E. Daniel | B. Ng | Tyhiesia Donald | H. Alsharhan | Katherine R. Yearwood | Wallid Deb | Arend H Werners | S. Jin | Arend H. Werners | Earnest J P Daniel
[1] H. Freeze,et al. Is X‐linked, infantile onset ALG13‐related developmental and epileptic encephalopathy a congenital disorder of glycosylation? , 2021, Epilepsia.
[2] J. Jaeken,et al. Congenital disorders of glycosylation: Still "hot" in 2020. , 2020, Biochimica et biophysica acta. General subjects.
[3] Ji Wu,et al. ALG13 participates in epileptogenesis via regulation of GABAA receptors in mouse models , 2020, Cell Death Discovery.
[4] Undiagnosed Diseases Network,et al. Predominant and novel de novo variants in 29 individuals with ALG13 deficiency: Clinical description, biomarker status, biochemical analysis, and treatment suggestions , 2020, Journal of inherited metabolic disease.
[5] J. Jankovic,et al. Hyperkinetic movement disorders in congenital disorders of glycosylation , 2019, European journal of neurology.
[6] Priyanka Madaan,et al. X-Linked ALG13 Gene Variant as a Cause of Epileptic Encephalopathy in Girls , 2019, The Indian Journal of Pediatrics.
[7] Xueli Li,et al. Increased Clinical Sensitivity and Specificity of Plasma Protein N-Glycan Profiling for Diagnosing Congenital Disorders of Glycosylation by Use of Flow Injection-Electrospray Ionization-Quadrupole Time-of-Flight Mass Spectrometry. , 2019, Clinical chemistry.
[8] Ji Wu,et al. ALG13 Deficiency Associated with Increased Seizure Susceptibility and Severity , 2019, Neuroscience.
[9] Alexandros Kouris,et al. VarSome: the human genomic variant search engine , 2018, bioRxiv.
[10] F. Bastaki,et al. Single‐center experience of N‐linked Congenital Disorders of Glycosylation with a Summary of Molecularly Characterized Cases in Arabs , 2018, Annals of human genetics.
[11] T. Gadomski,et al. ALG13‐CDG in a male with seizures, normal cognitive development, and normal transferrin isoelectric focusing , 2017, American journal of medical genetics. Part A.
[12] J. Jaeken,et al. What is new in CDG? , 2017, Journal of Inherited Metabolic Disease.
[13] Deciphering Developmental Disorders Study,et al. Prevalence and architecture of de novo mutations in developmental disorders , 2017, Nature.
[14] Michael R. Johnson,et al. De Novo Mutations in SLC1A2 and CACNA1A Are Important Causes of Epileptic Encephalopathies. , 2016, American journal of human genetics.
[15] E. Bourel-ponchel,et al. Whole‐exome sequencing improves the diagnosis yield in sporadic infantile spasm syndrome , 2016, Clinical genetics.
[16] D. Valle,et al. GeneMatcher: A Matching Tool for Connecting Investigators with an Interest in the Same Gene , 2015, Human mutation.
[17] K. Nakayama,et al. Genomic analysis identifies candidate pathogenic variants in 9 of 18 patients with unexplained West syndrome , 2015, Human Genetics.
[18] Marc S. Williams,et al. Girls with Seizures Due to the c.320A>G Variant in ALG13 Do Not Show Abnormal Glycosylation Pattern on Standard Testing. , 2015, JIMD reports.
[19] H. Mefford,et al. The genetic landscape of infantile spasms. , 2014, Human molecular genetics.
[20] S. Kantarci,et al. X chromosome exome sequencing reveals a novel ALG13 mutation in a nonsyndromic intellectual disability family with multiple affected male siblings , 2014, American journal of medical genetics. Part A.
[21] De novo mutations in epileptic encephalopathies , 2013 .
[22] B. V. van Bon,et al. Diagnostic exome sequencing in persons with severe intellectual disability. , 2012, The New England journal of medicine.
[23] B. Ruotolo,et al. Integrating mass spectrometry of intact protein complexes into structural proteomics , 2012, Proteomics.
[24] Christian Gilissen,et al. Gene identification in the congenital disorders of glycosylation type I by whole-exome sequencing. , 2012, Human molecular genetics.
[25] Manuel Corpas,et al. DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. , 2009, American journal of human genetics.
[26] S. Nishimura,et al. Alg13p, the catalytic subunit of the endoplasmic reticulum UDP-GlcNAc glycosyltransferase, is a target for proteasomal degradation. , 2008, Molecular biology of the cell.
[27] N. Averbeck,et al. Membrane Topology of the Alg14 Endoplasmic Reticulum UDP-GlcNAc Transferase Subunit* , 2007, Journal of Biological Chemistry.
[28] H. Tachikawa,et al. Alg14 Recruits Alg13 to the Cytoplasmic Face of the Endoplasmic Reticulum to Form a Novel Bipartite UDP-N-acetylglucosamine Transferase Required for the Second Step of N-Linked Glycosylation* , 2005, Journal of Biological Chemistry.
[29] R. Contreras,et al. Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I. , 2003, Glycobiology.
[30] G. Matthijs,et al. Congenital disorders of glycosylation. , 2000, Trends in biochemical sciences.
[31] H. Freeze,et al. Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy. , 1998, The Journal of clinical investigation.